Gilead Sciences and Kite Pharma unveiled plans to boost their cell therapy manufacturing operations with the addition of three new sites while also entering a cooperative research and development agreement with the National Cancer Institute, which will develop adoptive cell therapies to treat patient-specific tumor neoantigens. Two of the sites are located in the US, in Maryland and California, and the third will be in Hoofddorp, Netherlands, which will manufacture its chimeric antigen receptor T-cell therapy Yescarta, or axicabtagene ciloleucel, for distribution in Europe.
Gilead, Kite to boost cell therapy operations with 3 new facilities
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.